SCHEMBL675668

SCHEMBL675668

CCCCC(N)c1ccc2c(n1)[nH]c1ccc(/C=C/c3ccc(OC)cc3)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.37
TAS1R1 Q7RTX1 2/20 0.37
AHR P35869 1/20 0.37
ALK Q9UM73 2/20 0.37
TDP1 Q9NUW8 1/20 0.35
KCNH2 Q12809 1/20 0.34
GLA P06280 2/20 0.34
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
TUBB1 Q9H4B7 2/20 0.33
POLB P06746 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675097 0.89 IP6K1 (0.37) ALKTDP1CYP1A2SMN1; SMN2KDM4E
SCHEMBL674938 0.87 ALK (0.38) ALKKCNH2NPC1CYP1A2CYP2C9
SCHEMBL677052 0.82 AHR (0.39) TAS1R3TAS1R1AHRALKTDP1
SCHEMBL675671 0.80 ALK (0.37) TAS1R3TAS1R1AHRALKGLA
SCHEMBL3725135 0.80 GHSR (0.42) AHRALKGLANPC1CYP1A2
SCHEMBL3725133 0.80 GHSR (0.42) AHRALKGLANPC1CYP1A2
SCHEMBL675008 0.80 ALK (0.48) TAS1R3TAS1R1AHRALKTDP1
SCHEMBL677055 0.79 ALK (0.37) TAS1R3TAS1R1AHRALKGLA
SCHEMBL675011 0.78 ALK (0.37) TAS1R3TAS1R1ALKTDP1GLA
SCHEMBL676437 0.78 AHR (0.39) AHRALKGLANPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 TAS1R3 3700/4885TAS1R1 3065/4885AHR 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.